Published in Mol Cell Biol on December 01, 1991
A novel shuttling protein, 4E-T, mediates the nuclear import of the mRNA 5' cap-binding protein, eIF4E. EMBO J (2000) 2.37
Functional interaction of the v-Rel and c-Rel oncoproteins with the TATA-binding protein and association with transcription factor IIB. Mol Cell Biol (1993) 1.70
Hyperphosphorylation of mutant influenza virus matrix protein, M1, causes its retention in the nucleus. J Virol (1995) 1.55
The regulation of protein transport to the nucleus by phosphorylation. Biochem J (1995) 1.52
Ser276 phosphorylation of NF-kB p65 by MSK1 controls SCF expression in inflammation. PLoS One (2009) 1.36
RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J (1995) 1.34
Two distinct mechanisms contribute to the constitutive activation of RelB in lymphoid cells. EMBO J (1994) 1.30
A novel NF-kappa B complex containing p65 homodimers: implications for transcriptional control at the level of subunit dimerization. Mol Cell Biol (1993) 1.26
p105, the NF-kappa B p50 precursor protein, is one of the cellular proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells. J Virol (1992) 1.24
The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation. J Virol (1992) 1.16
Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1. J Virol (1994) 1.12
The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J (1996) 1.12
Specific amino acid residues in the basic helix-loop-helix domain of SRC-3 are essential for its nuclear localization and proteasome-dependent turnover. Mol Cell Biol (2006) 1.07
The serum response factor nuclear localization signal: general implications for cyclic AMP-dependent protein kinase activity in control of nuclear translocation. Mol Cell Biol (1995) 1.04
The c-Rel Transcription Factor in Development and Disease. Genes Cancer (2011) 1.01
Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. EMBO J (1996) 1.01
Differential pp40I kappa B-beta inhibition of DNA binding by rel proteins. Mol Cell Biol (1993) 1.00
Regulation of c-Rel nuclear localization by binding of Ca2+/calmodulin. Mol Cell Biol (2003) 0.98
NF-kappa B/Rel family members are physically associated phosphoproteins. Biochem J (1994) 0.98
Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediators Inflamm (2010) 0.93
In vivo evolution of c-rel oncogenic potential. J Virol (1994) 0.92
Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation. J Virol (1994) 0.91
Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein. Mol Cell Biol (1999) 0.91
Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblasts. Mol Cell Biol (2001) 0.90
c-Rel plays a key role in deficient activation of B cells from a non-X-linked hyper-IgM patient. Blood (2006) 0.88
Temperature-sensitive transforming mutants of the v-rel oncogene. J Virol (1993) 0.86
Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids. J Virol (1994) 0.86
PEST-dependent cytoplasmic retention of v-Rel by I(kappa)B-alpha: evidence that I(kappa)B-alpha regulates cellular localization of c-Rel and v-Rel by distinct mechanisms. J Virol (1996) 0.86
The Regulation of NF-κB Subunits by Phosphorylation. Cells (2016) 0.86
Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity. Mol Cell Biol (2003) 0.85
Mutations in the DNA-binding and dimerization domains of v-Rel are responsible for altered kappa B DNA-binding complexes in transformed cells. J Virol (1995) 0.82
The conserved redox-sensitive cysteine residue of the DNA-binding region in the c-Rel protein is involved in the regulation of the phosphorylation of the protein. Biochem J (2000) 0.81
Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation. J Virol (2002) 0.79
Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo. Mol Cell Biol (1996) 0.78
A mutant v-rel with increased ability to transform B lymphocytes. J Virol (1995) 0.78
Evidence for an inhibitory feedback loop regulating simian virus 40 large T-antigen fusion protein nuclear transport. Biochem J (1996) 0.77
Nuclear Import of JAK1 is Mediated by a Classical NLS and is Required for Survival of Diffuse Large B-cell Lymphoma. Mol Cancer Res (2016) 0.75
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A (1985) 68.48
Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol (1991) 15.04
Detection and quantification of phosphotyrosine in proteins. Methods Enzymol (1983) 11.89
The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell (1990) 9.37
Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature (1990) 9.31
Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell (1990) 9.24
New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol (1984) 8.63
The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim Biophys Acta (1991) 7.70
Protein kinase recognition sequence motifs. Trends Biochem Sci (1990) 7.49
DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell (1991) 6.63
Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem Sci (1990) 6.45
Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5' long terminal repeat and the start of the gag gene. Proc Natl Acad Sci U S A (1982) 5.56
Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. Nature (1991) 5.07
The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell (1990) 4.87
Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel. J Virol (1984) 4.17
A gradient of nuclear localization of the dorsal protein determines dorsoventral pattern in the Drosophila embryo. Cell (1989) 4.17
The graded distribution of the dorsal morphogen is initiated by selective nuclear transport in Drosophila. Cell (1989) 3.77
Rel-associated pp40: an inhibitor of the rel family of transcription factors. Science (1991) 3.76
High mutation rate of a spleen necrosis virus-based retrovirus vector. Mol Cell Biol (1986) 3.57
NF-kappa B, KBF1, dorsal, and related matters. Cell (1990) 3.51
Relocalization of the dorsal protein from the cytoplasm to the nucleus correlates with its function. Cell (1989) 2.85
c-rel activates but v-rel suppresses transcription from kappa B sites. Proc Natl Acad Sci U S A (1991) 2.65
The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Mol Cell Biol (1990) 2.47
The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today (1989) 2.41
Nuclear transport kinetics depend on phosphorylation-site-containing sequences flanking the karyophilic signal of the Simian virus 40 T-antigen. EMBO J (1989) 2.40
Oncogenic transformation by vrel requires an amino-terminal activation domain. Mol Cell Biol (1990) 2.15
Inhibition of transcription factors belonging to the rel/NF-kappa B family by a transdominant negative mutant. EMBO J (1991) 2.15
Nucleotide sequence of v-rel: the oncogene of reticuloendotheliosis virus. Proc Natl Acad Sci U S A (1983) 2.11
v-rel oncoproteins in the nucleus and in the cytoplasm transform chicken spleen cells. J Virol (1988) 2.08
vRel is an inactive member of the Rel family of transcriptional activating proteins. J Virol (1991) 2.04
Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T. Cell (1986) 1.96
Transactivation of gene expression by nuclear and cytoplasmic rel proteins. Mol Cell Biol (1989) 1.87
Cloning and expression of a chicken c-rel cDNA: unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryo fibroblasts. Oncogene (1990) 1.80
Dorsoventral pattern formation in Drosophila: signal transduction and nuclear targeting. Trends Genet (1991) 1.75
The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene (1990) 1.75
Hematopoietic cell transformation by reticuloendotheliosis virus: characterization of the genetic defect. Virology (1980) 1.73
p59v-rel, the transforming protein of reticuloendotheliosis virus, is complexed with at least four other proteins in transformed chicken lymphoid cells. J Virol (1988) 1.51
Malignant transformation by mutant Rel proteins. Trends Genet (1991) 1.41
Viral rel and cellular rel associate with cellular proteins in transformed and normal cells. Oncogene (1989) 1.39
The v-rel and c-rel proteins exist in high molecular weight complexes in avian and murine cells. Oncogene (1991) 1.32
Detection and characterization of the protein encoded by the chicken c-rel protooncogene. Oncogene Res (1988) 1.14
Reticuloendotheliosis virus REV-T(REV-A)-induced neoplasia: development of tumors within the T-lymphoid and myeloid lineages. J Virol (1990) 0.90
Serine phosphorylation of the v-rel oncogene product/pp40 complex. Biochem Biophys Res Commun (1988) 0.82
Mapping of the functional domains of the v-rel oncogene. Oncogene (1990) 0.81
Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene (1999) 4.76
Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene (2006) 3.49
Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ (2006) 3.04
Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol (2001) 2.74
Primary structure of elongation factor Tu from Escherichia coli. Proc Natl Acad Sci U S A (1980) 2.72
Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol (1989) 2.70
Solid-phase Edman degradation. An automatic peptide sequencer. Eur J Biochem (1971) 2.14
vRel is an inactive member of the Rel family of transcriptional activating proteins. J Virol (1991) 2.04
Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T. Cell (1986) 1.96
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci U S A (1998) 1.81
Cloning and expression of a chicken c-rel cDNA: unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryo fibroblasts. Oncogene (1990) 1.80
Development of mild extraction methods for the analysis of natural dyes in textiles of historical interest using LC-diode array detector-MS. Anal Chem (2005) 1.70
Neoplastic transformation by Notch requires nuclear localization. Mol Cell Biol (2000) 1.64
Solid-phase edman degradation: attachment of carboxyl-terminal homoserine peptides to an insoluble resin. FEBS Lett (1973) 1.61
Tyrosine phosphorylation of a 50K cellular polypeptide associated with the Rous sarcoma virus transforming protein pp60src. Mol Cell Biol (1982) 1.49
Sport, age, and sex specific incidence of sports injuries in Western Australia. Br J Sports Med (2000) 1.48
It's T-ALL about Notch. Oncogene (2008) 1.42
A mutant of Escherichia coli with an altered elongation factor Tu. Proc Natl Acad Sci U S A (1976) 1.36
Structure-function relationships in an antifreeze polypeptide. The role of neutral, polar amino acids. J Biol Chem (1992) 1.36
The C terminus of the NF-kappa B p50 precursor and an I kappa B isoform contain transcription activation domains. Nucleic Acids Res (1992) 1.36
LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim Biophys Acta (2001) 1.33
The amino acid sequence of elongation factor Tu of Escherichia coli. The complete sequence. J Biol Chem (1981) 1.33
A model for binding of an antifreeze polypeptide to ice. Biophys J (1992) 1.31
Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein. J Neuropathol Exp Neurol (1990) 1.30
Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem (1997) 1.25
Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene (1999) 1.24
p105, the NF-kappa B p50 precursor protein, is one of the cellular proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells. J Virol (1992) 1.24
The structure of bovine brain myelin proteolipid and its organization in myelin. Proc Natl Acad Sci U S A (1984) 1.21
Nonequilibrium antifreeze peptides and the recrystallization of ice. Cryobiology (1995) 1.21
Solid-phase methods in protein sequence analysis. Methods Biochem Anal (1980) 1.13
Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1. J Virol (1994) 1.12
Notch(ic)-ER chimeras display hormone-dependent transformation, nuclear accumulation, phosphorylation and CBF1 activation. Oncogene (2000) 1.10
v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence. Oncogene (1993) 1.07
Structure-function relationships in a type I antifreeze polypeptide. The role of threonine methyl and hydroxyl groups in antifreeze activity. J Biol Chem (1998) 1.07
The v-Rel oncoprotein blocks apoptosis and proteolysis of I kappa B-alpha in transformed chicken spleen cells. Oncogene (1995) 1.06
The validity of a four week self-recall of sports injuries. Inj Prev (2005) 1.06
The hedgehog processing pathway is required for NSCLC growth and survival. Oncogene (2012) 1.05
A synthetic peptide from myelin proteolipid protein induces experimental allergic encephalomyelitis. J Immunol (1988) 1.04
Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain. Oncogene (1993) 1.03
The active site of cetoacetate decarboxylase. J Am Chem Soc (1966) 1.03
Coupling techniques in solid-phase sequencing. Methods Enzymol (1977) 1.02
Suppression of erythroid but not megakaryocytic differentiation of human K562 erythroleukemic cells by notch-1. J Biol Chem (2000) 1.00
Effects of combined glutamine and serum deprivation on glucose control of hexose transport in mammalian fibroblast cultures. Proc Natl Acad Sci U S A (1980) 1.00
Characterization of mouse Trip6: a putative intracellular signaling protein. Gene (1999) 0.99
Repression of the chicken c-rel promoter by vRel in chicken embryo fibroblasts is not mediated through a consensus NF-kappa B binding site. Oncogene (1991) 0.99
Amino acid sequence of bovine white matter proteolipid. Arch Biochem Biophys (1983) 0.98
Location of the site of methylation in elongation factor Tu. FEBS Lett (1979) 0.98
Structure-function relationships in an antifreeze polypeptide. The effect of added bulky groups on activity. J Biol Chem (1993) 0.98
Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity. Oncogene (2006) 0.97
Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene (2009) 0.97
Amino acid sequence of a new type of antifreeze protein, from the longhorn sculpin Myoxocephalus octodecimspinosis. FEBS Lett (1997) 0.97
A D-antifreeze polypeptide displays the same activity as its natural L-enantiomer. FEBS Lett (1993) 0.96
The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts. Oncogene (1993) 0.96
Incidence and risk factors for injury in non-elite Australian Football. J Sci Med Sport (2004) 0.94
Bcl-2 and CrmA have different effects on transformation, apoptosis and the stability of I kappa B-alpha in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins. Oncogene (1996) 0.94
Gene duplication in bovine brain myelin proteolipid and homology with related proteins. FEBS Lett (1983) 0.93
NF-kappa B p100 is one of the high-molecular-weight proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells. J Virol (1993) 0.92
The evolution of elongation factors Tu and G by gene duplication. FEBS Lett (1978) 0.92
LIM domain-containing protein trip6 can act as a coactivator for the v-Rel transcription factor. Gene Expr (1999) 0.92
AAT1, a gene encoding a mitochondrial aspartate aminotransferase in Saccharomyces cerevisiae. Biochim Biophys Acta (1992) 0.92
Genetic analysis of growth inhibition by GAL4-L kappa B-alpha in Saccharomyces cerevisiae. Cell Growth Differ (1995) 0.91
The spleen necrosis virus int gene product expressed in Escherichia coli has DNA binding activity and mediates att and U5-specific DNA multimer formation in vitro. Virology (1987) 0.91
Amino-acid sequence and glycan structures of cysteine proteases with proline specificity from ginger rhizome Zingiber officinale. Eur J Biochem (2000) 0.91
Amino acid sequence of elongation factor Tu. Sequence of a region containing the thiol group essential for GTP binding. FEBS Lett (1975) 0.90
The lysine binding sites of human plasminogen. Evidence for a critical tryptophan in the binding site of kringle 4. J Biol Chem (1981) 0.90
Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL. Oncogene (2008) 0.90
Ubiquitin-activating enzyme (E1) isoforms in lens epithelial cells: origin of translation, E2 specificity and cellular localization determined with novel site-specific antibodies. Exp Eye Res (2001) 0.90
The 2.1 A structure of a cysteine protease with proline specificity from ginger rhizome, Zingiber officinale. Biochemistry (1999) 0.90
Myelin proteolipid protein: minimum sequence requirements for active induction of autoimmune encephalomyelitis in SWR/J and SJL/J mice. J Neuroimmunol (1992) 0.89
Surgeon-operated ultrasonography in a one-stop shoulder clinic. Ann R Coll Surg Engl (2011) 0.89
A conditional mutant of vRel containing sequences from the human estrogen receptor. Virology (1993) 0.88
A hydrophobic tryptic peptide from bovine white matter proteolipid. Biochim Biophys Acta (1982) 0.87
Temperature-sensitive transforming mutants of the v-rel oncogene. J Virol (1993) 0.86
Isolation and characterization of an antifreeze protein from the longhorn sculpin, Myoxocephalus octodecimspinosis. Biochim Biophys Acta (1998) 0.86
Arthroscopic capsular release for idiopathic frozen shoulder with intra-articular injection and a controlled manipulation. Ann R Coll Surg Engl (2014) 0.85
Purification and characterization of multiple forms of the pineapple-stem-derived cysteine proteinases ananain and comosain. Biochem J (1994) 0.85
Total synthesis of the NF-kappa B inhibitor (-)-cycloepoxydon: utilization of tartrate-mediated nucleophilic epoxidation. J Am Chem Soc (2001) 0.85
Artificial antifreeze polypeptides: alpha-helical peptides with KAAK motifs have antifreeze and ice crystal morphology modifying properties. FEBS Lett (1999) 0.85
Characterization of a chicken cDNA encoding the retinoblastoma gene product. Biochim Biophys Acta (1994) 0.84
A 1H-NMR study of isolated domains from human plasminogen. Structural homology between kringles 1 and 4. Eur J Biochem (1983) 0.84
Structure-function relationships in an antifreeze polypeptide. The role of charged amino acids. J Biol Chem (1993) 0.84
GAL4-I kappa B alpha and GAL4-I kappa B gamma activate transcription by different mechanisms. Nucleic Acids Res (1993) 0.83
Amino acid sequence of elongation factor Tu. Characterization and alignment of the cyanogen bromide fragments and location of the cysteine residues. FEBS Lett (1977) 0.83
Studies on the lysine-binding sites of human plasminogen. The effect of ligand structure on the binding of lysine analogs to plasminogen. Eur J Biochem (1980) 0.82
Monoclonal antibody specific for an activated RAS protein. Proc Natl Acad Sci U S A (1986) 0.82
Polynucleotide analogues. VIII. Poly 3-isoadenylic acid. Biochim Biophys Acta (1966) 0.82
Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein. Oncogene (2000) 0.82
Complete assignment of the aromatic proton magnetic resonance spectrum of the kringle 1 domain from human plasminogen: structure of the ligand-binding site. Biochemistry (1987) 0.81
Biological activities of 3-isoadenosine. Biochim Biophys Acta (1966) 0.81
The amino acid sequence of a dimeric myoglobin from the gastropod mollusc, Busycon canaliculatum L. FEBS Lett (1977) 0.81
Proto-oncogenes and plasticity in cell signaling. Cold Spring Harb Symp Quant Biol (1994) 0.80
Three mutations in v-Rel render it resistant to cleavage by cell-death protease caspase-3. Biochim Biophys Acta (2001) 0.80
Analogous amino acid sequences in myelin proteolipid and viral proteins. FEBS Lett (1986) 0.80
Acetoacetate decarboxylase. Subunits and properties. Biochemistry (1966) 0.80
Covalent immobilization of proteins and peptides for solid-phase sequencing using prepacked capillary columns. Anal Biochem (1990) 0.80
Identification of thiol groups and a disulfide crosslink site in bovine myelin proteolipid protein. FEBS Lett (1989) 0.79
Bromomesaconic and bromocitraconic acids. Potential active site labeling reagents for dicarboxylic acid metabolizing enzymes. J Med Chem (1971) 0.79